A development program for a therapy in which patients’ own mesenchymal stem cells are genetically edited ex vivo and re-administered, advancing SR-GT1’s clinical-trial drug manufacturing and transition to an investigator-initiated clinical trial. The program aims to bring gene therapy into clinical use with support from AMED funding.